Steatotic Liver Disease and the “Point of No Return” in the Development of Metabolic Disorders

Documenti analoghi

• Is Glucose Intolerance a Precursor of Cachexia in Patients With Liver Cirrhosis?
  di: Tsutomu Nishida, et al.
  Pubblicazione: (2025)
• Response to the Letter “Steatotic Liver Disease and the ‘Point of No Return’ in the Development of Metabolic Disorders”
  di: Yoshihiro Kamada
  Pubblicazione: (2026)
• Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID‐19
  di: Kengo Matsumoto, et al.
  Pubblicazione: (2024)
• Steatotic Liver Disease: A Key Related Risk Factor in the Emergence of Metabolic Syndrome‐Related Disorders
  di: Yoshihiro Kamada, et al.
  Pubblicazione: (2025)
• Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease
  di: Oguzhan Celik, et al.
  Pubblicazione: (2026)